Loading
A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Philogen S.p.A., now recruiting.
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT04443010 by Philogen S.p.A., with 226 participants planned, started 2021-01-20 and due to reach its primary completion in 2026-10. Interventions recorded: Onfekafusp alfa and Temozolomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Philogen S.p.A., Glioma & glioblastoma and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/